Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Drug Use Investigation for REVOLADE (ITP)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Novartis Identifier:
First received: June 9, 2011
Last updated: March 16, 2016
Last verified: March 2016

To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety and efficacy.

<Priority investigation item> Thromboembolism

Condition Intervention
Purpura, Thrombocytopaenic, Idiopathic
Drug: Eltrombopag

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura)

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • The number of subjects with any adverse events treated with REVOLADE [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Appearance of thromboembolism [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    If thromboembolism is appeared or not in subjects who received REVOLADE will be investigated throughout the study period

Estimated Enrollment: 1000
Study Start Date: December 2010
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Subjects prescribed REVOLADE
Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period
Drug: Eltrombopag


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
All Japanese subjects with chronic idiopathic thrombocytopenic purpura who recieve REVOLADE

Inclusion Criteria:

  • Subjects with chronic idiopathic thrombocytopenic purpura

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01416311

Sponsors and Collaborators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Identifier: NCT01416311     History of Changes
Other Study ID Numbers: 114877 
Study First Received: June 9, 2011
Last Updated: March 16, 2016
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Purpura, Thrombocytopenic, Idiopathic
Purpura, Thrombocytopenic
Blood Coagulation Disorders
Hematologic Diseases
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Blood Platelet Disorders
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases processed this record on October 27, 2016